{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:50:50Z","timestamp":1791237050942,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011772","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011772","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011772","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011772","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011772","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jaip.2018.12.025","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T01:03:07Z","timestamp":1547514187000},"page":"1599-1609.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial"],"prefix":"10.1016","volume":"7","author":[{"given":"Gabriel","family":"Gastaminza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Azofra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge M.","family":"Nunez-Cordoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Baeza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Echechip\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Gaig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca Esther","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moises","family":"Labrador-Horrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Sala-Cunill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Sabat\u00e9","family":"Bresc\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Beristain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Qui\u00f1ones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen D\u00edaz","family":"Donado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Zubeldia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2018.12.025_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10286-017-0418-6","article-title":"Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management","volume":"28","author":"Fukunaga","year":"2018","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.jaip.2018.12.025_bib2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1046\/j.1365-2133.1999.02767.x","article-title":"The extent and nature of disability in different urticarial conditions","volume":"140","author":"Poon","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2018.12.025_bib3","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/cea.13023","article-title":"Cholinergic urticaria patients of different age groups have distinct features","volume":"47","author":"Asady","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.12.025_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000446787","article-title":"New etiology of cholinergic urticaria","volume":"51","author":"Tokura","year":"2016","journal-title":"Curr Probl Dermatol"},{"key":"10.1016\/j.jaip.2018.12.025_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0923-1811(94)90088-4","article-title":"Demonstration of sweat allergy in cholinergic urticaria","volume":"7","author":"Adachi","year":"1994","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaip.2018.12.025_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2332\/allergolint.13-OA-0611","article-title":"Elevated serum IgE against MGL_1304 in patients with atopic dermatitis and cholinergic urticaria","volume":"63","author":"Hiragun","year":"2014","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2018.12.025_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2017.03.002","article-title":"Sweat allergy: extrinsic or intrinsic?","volume":"87","author":"Hiragun","year":"2017","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaip.2018.12.025_bib8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2133.2008.08862.x","article-title":"Sweat antigen induces histamine release from basophils of patients with cholinergic urticaria associated with atopic diathesis","volume":"160","author":"Takahagi","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2018.12.025_bib9","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1046\/j.1365-2133.2000.03845.x","article-title":"Cholinergic urticaria associated with acquired generalized hypohidrosis: report of a case and review of the literature","volume":"143","author":"Itakura","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2018.12.025_bib10","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000248603","article-title":"Cholinergic urticaria, passive transfer experiments from human to monkey","volume":"177","author":"Murphy","year":"1988","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaip.2018.12.025_bib11","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0190-9622(94)70267-5","article-title":"Prevalence of cholinergic urticaria in young adults","volume":"31","author":"Zuberbier","year":"1994","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2018.12.025_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/2229-5178.105493","article-title":"Prevalence of cholinergic urticaria in Indian adults","volume":"4","author":"Godse","year":"2013","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.jaip.2018.12.025_bib13","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.jaci.2018.01.031","article-title":"Chronic inducible urticaria: a systematic review of treatment options","volume":"141","author":"Dressler","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.025_bib14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000246281","article-title":"Double-blind crossover study of high-dose cetirizine in cholinergic urticaria","volume":"193","author":"Zuberbier","year":"1996","journal-title":"Dermatology"},{"key":"10.1016\/j.jaip.2018.12.025_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/ijd.13808","article-title":"Successful treatment of refractory cholinergic urticaria with omalizumab","volume":"57","author":"Koumaki","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2018.12.025_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ad.2016.07.018","article-title":"Omalizumab in the treatment of chronic inducible urticaria","volume":"108","author":"Chicharro","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jaip.2018.12.025_bib17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamadermatol.2013.8705","article-title":"Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria","volume":"150","author":"Metz","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2018.12.025_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1398-9995.2007.01591.x","article-title":"Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy","volume":"63","author":"Metz","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.12.025_bib19","article-title":"Real life treatment of cholinergic urticaria with omalizumab","author":"Altrichter","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.025_bib20","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1111\/j.1365-2230.2009.03748.x","article-title":"Failure of omalizumab in cholinergic urticaria","volume":"35","author":"Sabroe","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2018.12.025_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/cea.12668","article-title":"Comparable actions of omalizumab on mast cells and basophils","volume":"46","author":"Serrano-Candelas","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.12.025_bib22","doi-asserted-by":"crossref","first-page":"8985","DOI":"10.1038\/s41598-017-09361-4","article-title":"Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells","volume":"7","author":"Serrano-Candelas","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2018.12.025_bib23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence","volume":"141","author":"Maurer","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.025_bib24","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2017.01.042","article-title":"Omalizumab is effective in symptomatic dermographism\u2014results of a randomized placebo-controlled trial","volume":"140","author":"Maurer","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.025_bib25","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jaci.2017.01.043","article-title":"Omalizumab is effective in cold urticaria\u2014results of a randomized placebo-controlled trial","volume":"140","author":"Metz","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.025_bib26","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/all.12884","article-title":"The definition, diagnostic testing, and management of chronic inducible urticarias \u2013 The EAACI\/GA2LEN\/EDF\/UNEV consensus recommendations 2016 update and revision","volume":"71","author":"Magerl","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.12.025_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1365-2222.2002.01305.x","article-title":"Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics","volume":"32","author":"Sanz","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.12.025_bib28","first-page":"426","article-title":"Adaptation and validation of the Spanish version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL)","volume":"18","author":"Valero","year":"2008","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.025_bib29","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","article-title":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria","volume":"137","author":"Kaplan","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.025_bib30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.025_bib31","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaci.2009.09.012","article-title":"Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge","volume":"125","author":"Eckman","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.025_bib32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1468-3083.2011.04017.x","article-title":"Cholinergic urticaria: pathogenesis-based categorization and its treatment options","volume":"26","author":"Nakamizo","year":"2012","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2018.12.025_bib33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2500\/aap.2009.30.3237","article-title":"A\u00a0case of severe refractory chronic urticaria: a novel method for evaluation and treatment","volume":"30","author":"Otto","year":"2009","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2018.12.025_bib34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdermsci.2013.08.011","article-title":"Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis","volume":"73","author":"Metz","year":"2014","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaip.2018.12.025_bib35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjd.14540","article-title":"Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients","volume":"175","author":"Ghazanfar","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2018.12.025_bib36","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jaip.2017.10.001","article-title":"The Urticaria Activity Score\u2014validity, reliability, and responsiveness","volume":"6","author":"Hawro","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.12.025_bib37","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for chronic urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.12.025_bib38","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jaip.2018.04.003","article-title":"Predicting chronic spontaneous urticaria symptom return after omalizumab treatment discontinuation: exploratory analysis","volume":"6","author":"Ferrer","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.12.025_bib39","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0091-6749(98)70176-9","article-title":"Comparative studies of functional and binding assays for IgG anti-Fc RI (alpha-subunit) in chronic urticaria","volume":"101","author":"Ferrer","year":"1998","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.12.025_bib40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/ijd.12549","article-title":"The significance of hypersensitivity to autologous sweat and serum in cholinergic urticaria: cholinergic urticaria may have different subtypes","volume":"54","author":"Kim","year":"2015","journal-title":"Int J Dermatol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819300510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819300510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:18:11Z","timestamp":1761974291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219819300510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S2213219819300510"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2018.12.025","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734877232.793555555","asserted-by":"object"}]},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2018.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}